Determining the Mechanisms of Loss of CAR T Cell Persistence

Launched by UNIVERSITY COLLEGE, LONDON · Mar 29, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well a type of treatment called CAR T-cell therapy works for patients with a specific type of blood cancer known as acute lymphoblastic leukemia (ALL) who haven't responded to other treatments or have relapsed. The goal of the study is to understand why these CAR T-cells, which are designed to help the body fight cancer, may not stay effective over time. Researchers will observe the patients and track changes in the CAR T-cells to figure out what factors might influence their persistence or effectiveness.

To be eligible for this trial, participants need to be children or young adults aged 25 or younger who are set to receive a specific CAR T-cell treatment called Tisagenlecleucel. They must also provide written permission to participate. Those currently receiving a different type of CAR T-cell therapy or who may have difficulty following the study rules will not be included. Patients involved in this study can expect to be closely monitored and contribute valuable information that could help improve treatment for future patients with ALL.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
• • 2. Written informed consent
• Exclusion Criteria:
• • 1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
• • 2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol